Japanese multinational NEC has bought the Norway-based bioinformatics firm OncoImmunity, which develops proprietary machine learning software to support cancer R&D.
The FDA has approved a second biosimilar of Roche’s leukaemia drug Rituxan, along with yet another biosimilar of AbbVie’s inflammatory diseases blockbuster Humira.
In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies.